Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD

Figures & data

Figure 1 Patient screening and inclusion flow chart.

Abbreviation: NSCLC, non-small-cell lung cancer.

Table 1 Patient characteristics and baseline physiological data

	Chemotherapy group	Non-chemotherapy group	P-value
N	45	24
Male sex	37	18	0.6919
Age, years	67.89±7.18	69.50±6.82	0.2668
Smoking history, never smoker	6	1	0.4339
Smoking status, pack-years	46.78±26.52	50.11±34.76	0.854
Symptoms related to COPD			0.8678
No symptom, n	18	8
Cough and sputum, n	6	2
Dyspnea, n	2	1
Cough, sputum, and dyspnea, n	19	13
PS score			0.2044
1	11	4
2	34	18
3	0	2
Histology			0.1134
Adenocarcinoma	16	12
Squamous cell carcinoma	22	10
Large cell carcinoma	1	2
Adenosquamous carcinoma	6	0
Stage			0.7925
IA	2	0
IIA	0	1
IIB	3	2
IIIA	11	4
IIIB	11	6
IV	18	11
Lung function test
FEV1, L	1.06±0.31	1.02±0.25	0.8353
FEV1, %	39.38±8.28	41.71±8.87	0.1776
FVC, L	2.20±0.58	1.99±0.40	0.0876
FVC, %	63.14±12.49	63.80±11.76	0.9598
GOLD grade			0.8163
Severe, n	35	20
Very severe, n	10	4
Laboratory test
ALB, g/L	38.33±4.31	37.13±3.59	0.2468
AST, U/L	20.05±16.29	19.17±9.41	0.5164
ALT, U/L	17.97±12.84	17.32±12.81	0.6276
r-GT, U/L	48.47±97.56	31.29±23.44	0.2867
Cr, umol/L	70.14±16.10	65.15±14.92	0.3225

Abbreviations: ALB, albumin; ALT, alanyl transferase; AST, aspartate transaminase; Cr, creatinine; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PS, performance status; r-GT, r-glutamyltransferase.

Figure 2 Kaplan–Meier curves for chemotherapy and non-chemotherapy patients.

Table 2 Summary of the results of multivariate analysis of independent risk factors related to the prognosis of lung cancer patients

	HR	95% CI	P-value
Chemotherapy	0.4464	0.2495–0.7988	0.0066
Male	0.8527	0.4461–1.6298	0.6297
Age	1.0021	0.9609–1.0451	0.9214
Histologya	1.4422	0.6959–2.9889	0.3247
Stageb	1.9098	0.8607–4.2375	0.1116
PS score	1.5155	0.7523–3.0529	0.2446
GOLD gradec	1.3856	0.7149–2.6857	0.3341
Respiratory symptoms	1.0518	0.6032–1.8342	0.8586

Notes:

a Adenocarcinoma and squamous cell carcinoma vs adenosquamous carcinoma + large cell carcinoma.

b Stage IA + IIA + IIB vs IIIA + IIIB + IV.

c Grade 3 vs grade 4.

Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease; PS, performance status.

Table 3 Toxicity profile of patients in the chemotherapy group (unit: cases)

	Grade 1	Grade 2	Grade 3	Grade 4	Total
Leukopenia	5	6	3	1	15
Neutropenia	5	4	4	1	14
Anemia	7	3	4	0	14
Thrombocytopenia	2	0	4	0	6
Gastrointestinal reaction	12	4	1	0	17
Fatigue	9	5	2	0	16